logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
10 October, 2018

Europe approves Verzenios, from Lilly, for the treatment of advanced breast cancer

Source: actasanitaria.com The European Commission has authorized the commercialization of Verzenios (abemaciclib), from the pharmaceutical company Lilly, as a treatment of locally advanced or metastatic breast […]
Like?
Leer más
8 October, 2018

Genetic mutations also alter the nature of clinical trials

Source: immedicohospitalario.es New ways of researching and developing drugs, in their most advanced oncological aspects, urge health administrations, hospitals, patients and their organizations, Research Ethics Committees […]
Like?
Leer más
5 October, 2018

VHIO develops a precision immunotherapy for breast cancer

Source: redaccionmedica.com Researchers at the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona have achieved that immunotherapy attacks only the tumor cells of a type of […]
Like?
Leer más
3 October, 2018

Nobel Prize for Medicine 2018 for cancer immunotherapy

Source: IntraMed The American James Allison and the Japanese Tasuku Honjo have won the Nobel Prize for Medicine 2018. The jury of the Karolinska Institute in […]
Like?
Leer más
26 September, 2018

EMA gives a positive opinion to Gilenya, from Novartis, for minors with multiple sclerosis

Source: actasanitaria.com The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of the drug Gilenya (fingolimod), […]
Like?
Leer más
21 September, 2018

ISCIII will represent Spain in the largest research appointment in Europe

Source: redaccionmedica.com The director of the Health Institute Carlos III (ISCIII), Raquel Yotti Álvarez, in charge of the head of the Spanish delegation at the opening […]
Like?
Leer más
18 September, 2018

Lilly Foundation awards a study of protein kinase in liver disease

Source: Actasanitaria.com Within the framework of the 41st Annual Congress of the Spanish Society of Biochemistry and Molecular Biology (SEBBM), which is being held in Santander, […]
Like?
Leer más
13 September, 2018

AstraZeneca Foundation encourages young talent with 80,000 euros

Source: redaccionmedica.com The AstraZeneca Foundation, in collaboration with the Carlos III Health Institute, has announced the winners of the IV Young Researchers Awards, a recognition that […]
Like?
Leer más
14 March, 2018

Clinical Trials Area of the Hospital Pharmacy Service

Distefar, considera que las funciones que se llevan a cabo en el servicio de farmacia hospitalaria, dentro del entorno de un estudio con medicamentos, son fundamentales […]
Like?
Leer más
Previous page
1234567891011121314151617181920212223242526

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Legal warning
  • Privacy policy
  • Cookies policy
  • Contact

© 2026 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.

    Distefar del Sur
    Gestión de la medicación Reembolso de gastos a pacientes Suministro de dispositivos médicos Destrucción Calibración de dispositivos médicos Importación y etiquetado Enmascaramiento. Fabricación de placebos
    Blog
    Certificaciones RSE
    Clientes
    Hoja de Validación / Reembolso de Gastos
    Contactar
    +34 955 776 767 info@distefar.com
    ES ES EN EN